» Articles » PMID: 25887629

Choroidal Thickness Changes After Photodynamic Therapy and Recurrence of Chronic Central Serous Chorioretinopathy

Overview
Journal Am J Ophthalmol
Specialty Ophthalmology
Date 2015 Apr 19
PMID 25887629
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To investigate long-term changes in subfoveal choroidal thickness (SCT) after photodynamic therapy (PDT) and their relationship with chronic central serous chorioretinopathy (CSC) recurrence.

Design: Retrospective, observational, comparative case series.

Methods: Fifty-seven eyes with chronic CSC (52 patients, ≥2 years follow-up) treated with half-fluence or half-dose PDT were divided into 2 groups: those with incomplete CSC resolution or subretinal fluid (SRF) recurrence (SRF+) and those with complete SRF absorption without disease recurrence (SRF-). The SCT was measured using spectral-domain optical coherence tomography and relative SCT ratios (follow-up SCT: baseline SCT ratio) were compared between the 2 groups.

Results: Mean follow-up period was 33.9 ± 9.9 months (range: 24-62 months). Four of 57 eyes (7%) had persistent SRF after PDT and 12 of 53 eyes (22.6%) had initial SRF resolution with SRF recurrence. The SRF+ group had a slower reduction in SCT during the first month (P < .001) and a higher relative SCT ratio than the SRF- group throughout follow-up (P < .001). The relative SCT ratio at 1 month was highly predictive of CSC recurrence (area under the curve = 0.902, 95% confidence interval: 0.823-0.982). Using a relative SCT ratio cutoff of 93.1%, sensitivity of this measure was 93.8% and specificity was 78.1%.

Conclusions: Those with incomplete SRF absorption or SRF recurrence had a slower SCT decline at 1 month and a higher SCT ratio throughout follow-up compared to those without CSC recurrence. The SCT changes may reflect PDT efficacy and help predict long-term recurrence and early treatment outcomes.

Citing Articles

Central serous chorioretinopathy: updates in the pathogenesis, diagnosis and therapeutic strategies.

Zhang X, Lim C, Chhablani J, Wong Y Eye Vis (Lond). 2023; 10(1):33.

PMID: 37430344 PMC: 10334588. DOI: 10.1186/s40662-023-00349-y.


Outer nuclear layer recovery as a predictor of visual prognosis in type 1 choroidal neovascularization of neovascular age-related macular degeneration.

Lee S, Kim K, Kim D, Chae J, Seo E Sci Rep. 2023; 13(1):5045.

PMID: 36977729 PMC: 10050211. DOI: 10.1038/s41598-023-32184-5.


Evaluation of Choroidal Thickness Using Optical Coherent Tomography: A Review.

Xie R, Qiu B, Chhablani J, Zhang X Front Med (Lausanne). 2021; 8:783519.

PMID: 34926529 PMC: 8677938. DOI: 10.3389/fmed.2021.783519.


Applications of Multimodal Imaging in Central Serous Chorioretinopathy Evaluation.

Ho M, Li G, Mak A, Ng D, Iu L, Lai F J Ophthalmol. 2021; 2021:9929864.

PMID: 34350034 PMC: 8328719. DOI: 10.1155/2021/9929864.


Incidence of central serous chorioretinopathy (2011-2018): a nationwide population-based cohort study of Japan.

Kido A, Miyake M, Tamura H, Hiragi S, Kimura T, Ohtera S Br J Ophthalmol. 2021; 106(12):1748-1753.

PMID: 34261662 PMC: 9685711. DOI: 10.1136/bjophthalmol-2021-319403.